Discover what’s new at Eisbach. Here we share the latest research insights, key developments, and relevant updates - clearly, concisely, and always up to date. A quick way to stay informed on what’s shaping our work right now.
Munich, 26.04.2023 : Eisbach Bio GmbH, a biotechnology company targeting the molecular machines that drive human disease, today announced the start of a Phase 1, first-in-human clinical trial for EIS-10700, a small molecule that targets the RNA helicase of SARS-CoV-2. Eisbach Bio is developing a COVID-19 antiviral as part of the EisCor2 project supported by the German Federal Ministry of Research (BMBF). The trial is designed to evaluate the safety, tolerability, and pharmaco